DAMIAN Pharma

Startseite
Schweiz
Walchwil
DAMIAN Pharma

Anrufen Wegbeschreibung Website Service kontaktieren

On a mission to develop + deliver first-of-a-kind solutions for patients with Primary Aldosteronism.

10/03/2026

Left untreated, (PA) can put your kidneys in jeopardy.

Learn about PA and our mission: DAMIANpharma.com

28/02/2026

Because (PA) continues to be under-diagnosed, being aware of symptoms like these could help you and your physician determine if getting screened is right for you.

Discover more about PA: DAMIANpharma.com

05/01/2026

Trying to cut back on your salt post-holiday? Opt for a healthier choice that delivers the salty flavor you crave with 95% less sodium than the alternative.

15/12/2025

The American Heart Association and American College of Cardiology have recently released updated hypertension guidelines. Importantly, these new guidelines represent the first time that specific recommendations have been proposed for (PA).

While previous guidelines have noted that all causes of secondary hypertension should be explored before diagnosing a patient with resistant hypertension, including PA, they failed to do more. The updated guidelines now describe in more detail patients that should be specifically screened for PA and, importantly, recommend not washing patients out of most antihypertensive agents before diagnostic testing. This is an important element since PA is diagnosed at very low rates, in part due to cumbersome diagnosis. The new guidelines should raise awareness of PA among cardiologists and support an increase in diagnosis among patients with hypertension, particularly those early in their disease.

Read the Full Article: https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356

24/11/2025

'Healthy Choices' and 'Holidays' don't often go hand-in-hand; but that makes it even more important for those with hypertension to monitor their intake. Heed our 'healthy choice' hack to help set yourself up for success!

06/11/2025

The Endocrine Society recently published new clinical practice guidelines for (PA). The revised guidelines are intended to improve the identification and diagnosis of patients with PA, a disease with significant long-term consequences but very low diagnostic rate.

Key among the new recommendations is that aldosterone suppression testing is now only indicated if the screening results show an intermediate probability for lateralizing PA. Additionally, the guidelines allow the empiric use of medical therapy in the absence of testing the blood for aldosterone and renin levels (the ‘aldosterone-to-renin ratio’) if the feasibility for such testing is low. The authors note that even subclinical (i.e. early) PA is negatively associated with cardiovascular disease indicators and that ‘the morbidity and mortality associated with PA are largely preventable.’

Read the Full Article: https://www.endocrine.org/clinical-practice-guidelines/primary-aldosteronism-2

29/09/2025

Take this friendly tip for with a grain of salt (substitutes). Your heart will thank you!

11/08/2025

Too much sodium is associated with high blood pressure and can lead to stroke. A recently published study by Ding et al. enrolled patients with a history of stroke to evaluate the use of salt substitutes on the incidence of recurrent stroke.

In a substudy of the Salt Substitute and Stroke Study (SSaSS) in China, more than 15,000 stroke patients were given either regular salt or a salt substitute (75% NaCl, 25% KCl) and followed for an average of five years. The primary outcome was diagnosis of recurrent stroke following adjudication by an independent committee.

Investigators found that using the salt substitute reduced the risk of both fatal and nonfatal recurrent stroke, providing further evidence that sodium-reducing measures may reduce some secondary outcomes of high blood pressure. However, caution should be taken in patients who may be at-risk for hyperkalemia.

Read More: https://jamanetwork.com/journals/jamacardiology/article-abstract/2829790

14/07/2025

Learn about : DAMIANpharma.com

16/06/2025

As has been reported in other studies, data from the Japan (PA) Study confirm that high aldosterone levels in patients with PA increase the risk for cardiovascular (CV) events compared with patients with essential hypertension.

In their study, Ohno et al. also investigated what additional factors may confer a higher CV risk to PA patients. The analysis showed that PA patients with hypokalemia (low potassium) or the unilateral subtype (a benign adenoma on one adrenal gland) have an even higher risk of cardiovascular disease. Further, they provide evidence that aldosterone levels higher than 125 pg/mL also confer a higher risk.

The authors recommend that patients with high aldosterone, hypokalemia, or unilateral disease be preferentially diagnosed for PA and treated with PA-specific drugs.

Read More: https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.117.10263?doi=10.1161/HYPERTENSIONAHA.117.10263

Adresse

Walchwil

Telefon

+41616010978

Website

http://damianpharma.com/

Benachrichtigungen

Erfahren Sie als Erste/r von Neuigkeiten und Aktionen: Wir schicken Ihnen eine E-Mail, wenn DAMIAN Pharma etwas veröffentlicht. Ihre E-Mail-Adresse wird für keinen anderen Zweck verwendet, und Sie können sich jederzeit abmelden.